Trial Profile
A Phase III Randomized, Open- Label Multi-center Study of Nilotinib Versus Imatinib in Adult Patients With Ph+ Chronic Myelogenous Leukemia in Chronic Phase (CML-CP) Who Have a Suboptimal Cytogenetic Response (CyR) on Imatinib
Status:
Discontinued
Phase of Trial:
Phase III
Latest Information Update: 20 Jan 2022
Price :
$35
*
At a glance
- Drugs Nilotinib (Primary) ; Imatinib
- Indications Chronic myeloid leukaemia
- Focus Registrational; Therapeutic Use
- Acronyms ENEST
- Sponsors Novartis
- 19 Jan 2022 This trial has been completed in Greece (End Date: 29 Mar 2009), according to European Clinical Trials Database record.
- 05 Oct 2021 This trial has discontinued in France, as per European Clinical Trials Database record
- 03 Jul 2012 Planned number of patients changed from 586 to 608 and additional trial locations added as reported by European Clinical Trials Database record.